Gene therapy of cancer: use of IL-2 gene transfer and kinetics of local T and NK cell subsets.
Experiments were designed to compare the efficacy of recombinant IL-2 immunotherapy and IL-2 gene therapy of i.p. growing murine plasmacytoma X63-Ag8.653. The kinetics of peritoneal exudate mononuclear cells were monitored during the progression and gene therapy of the plasmacytoma, using cytofluorometric analysis and monoclonal antibodies against T and NK cell subsets. It has been found that the percentage of mice protected against plasmacytoma transplants was higher in mice treated by transfer of genetically manipulated IL-2-producing plasmacytoma cells as compared to the mice repeatedly injected with recombinant IL-2. Intraperitoneal inoculation of the X63-Ag8.653 plasmacytoma led in most of the inoculated mice to an increased percentage of NK+, ASGM1+, Thy 1.2+, CD3+ and TCR alpha beta+ cells in the peritoneal fluid. The presence of macroscopically detectable i.p. tumours was accompanied by a higher increase in the percentage of NK+ and TCR gamma delta+ cells. Local IL-2 gene therapy of the plasmacytoma either prevented or diminished an increase in the percentage of CD3+, Thy 1.2+ and TCR alpha beta+ lymphocytes.
Bubeník
J
J
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague.
Zeuthen
J
J
Bubeníková
D
D
Símová
J
J
Jandlová
T
T
D000818:Animals; D015316:Genetic Therapy / Q000379:methods*; D007111:Immunity, Cellular; D007376:Interleukin-2 / Q000235:genetics* / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000166:cytology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010954:Plasmacytoma / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000166:cytology*; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D011994:Recombinant Proteins